Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex

Objective: We aimed to analyse the effects of age and sex on performance and cost for patients with chronic peripheral neuropathic pain (PNP) who have started treatment with brand name gabapentin versus generic gabapentin (EFG). Methods: We conducted a retrospective multicentre study using electroni...

Full description

Bibliographic Details
Main Authors:	R. Navarro-Artieda, J. Rejas-Gutiérrez, M. Pérez-Paramo, A. Sicras-Mainar
Format:	Article
Language:	English
Published:	Elsevier España 2018-04-01
Series:	Neurología (English Edition)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2173580818300105

Similar Items

Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain
by: Sicras-Mainar A, et al.
Published: (2015-06-01)

Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
by: A. Sicras-Mainar, et al.
Published: (2018-12-01)

Influencia de la sustitución de medicamentos de marca por genéricos en el cumplimiento terapéutico de la hipertensión arterial y la dislipidemia Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia
by: Antoni Sicras Mainar, et al.
Published: (2010-12-01)

A Cost-Consequences analysis of the effect of Pregabalin in the treatment of peripheral Neuropathic Pain in routine medical practice in Primary Care settings
by: Torrades Sandra, et al.
Published: (2011-01-01)

Is Brand Name Best? Brand name versus generic pharmaceuticals in clinical practice
by: Andrea Bakker
Published: (2017-06-01)

Efecto de la edad y el género sobre las consecuencias clínicas y económicas del tratamiento con especialidad farmacéutica de marca o genérica en pacientes con dolor neuropático periférico en práctica clínica habitual
by: R. Navarro-Artieda, et al.
Published: (2018-04-01)

Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact
by: Antoni Sicras-Mainar, et al.
Published: (2014-12-01)

Los adjusted clinicals groups: Un sistema de clasificación de pacientes por ajuste de riesgos
by: Antonio Sicras-Mainar, et al.
Published: (2013-06-01)

Validación retrospectiva del Johns-Hopkins ACG Case-Mix System en la población Española Validating the Adjusted Clinical Groups [ACG] Case-mix System in a Spanish population setting: a multicenter study
by: Antoni Sicras-Mainar, et al.
Published: (2009-06-01)

Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences.
by: Antoni Sicras-Mainar, et al.
Published: (2014-01-01)

Cost and clinical consequences of smoking cessation in outpatients after cardiovascular disease: a retrospective cohort study
by: Sicras-Mainar A, et al.
Published: (2013-08-01)

Opinión de los médicos de atención primaria sobre el uso de un sistema de ajuste de riesgos: Los adjusted clinical groups
by: Antoni Sicras-Mainar, et al.

Opinión de los médicos de atención primaria sobre el uso de un sistema de ajuste de riesgos: Los adjusted clinical groups
by: Antoni Sicras-Mainar, et al.

Combinación de metformina frente a inhibidores de la dipeptidilpeptidasa y sulfonilureas en el tratamiento de la diabetes tipo 2: impacto clínico y económico
by: Antoni Sicras-Mainar, et al.

Combinación de metformina frente a inhibidores de la dipeptidilpeptidasa y sulfonilureas en el tratamiento de la diabetes tipo 2: impacto clínico y económico
by: Antoni Sicras-Mainar, et al.

Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients
by: Antoni Sicras-Mainar, et al.
Published: (2015-02-01)

Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis
by: Sicras-Mainar A, et al.
Published: (2015-12-01)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
by: Sicras-Mainar A, et al.
Published: (2014-06-01)

Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients ( 2015;39:74-81)
by: Antoni Sicras-Mainar, et al.
Published: (2015-04-01)

Name Brand and Generic Brand Competition：An analysis of Generic Brand Strategy of Market and Channel Investment Portfolio
by: Tyng-Yu Liou, et al.
Published: (2013)

Generic Drugs : Physician Prescribing Practices for Brand Name and Generic Medications
by: George, Tamuno Raymond
Published: (2016)

Clinical validity of a population database definition of remission in patients with major depression
by: Salvatella-Pasant Jordi, et al.
Published: (2010-02-01)

Clinical and economic impact of generic versus brand name meropenem use in an intensive care unit in Colombia
by: Karen Ordóñez, et al.
Published: (2019-07-01)

The concept of: Generic drugs and patented drugs Vs brand name drugs and non-proprietary (generic) name drugs.
by: Karan eThakkar, et al.
Published: (2013-09-01)

The Utilization of Brand Name Drugs and Generic Drugs in Taiwan
by: Ho-Chuan Chen, et al.
Published: (2006)

Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study
by: Sicras-Mainar A, et al.
Published: (2020-12-01)

Evaluation on Therapeutic Equivalence of Generic and Brand-name Cardiovascular Medicines
by: Meng-KengTsay, et al.
Published: (2018)

Posibilidades de los Grupos Clínicos Ajustados (Ajusted Clinical Groups-ACGs) en el ajuste de riesgos de pago capitativo
by: Antoni Sicras-Mainar, et al.
Published: (2006-01-01)

An open-label prospective clinical study of the efficacy and tolerability of brand-name and generic levetiracetam in the monotherapy of focal epilepsy in adults
by: V. A. Karlov, et al.
Published: (2018-07-01)

Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain
by: Javier Rejas-Gutierrez, et al.
Published: (2021-04-01)

Name Brand and Generic brand Competition：The OptimalPosition for Store Brand under Channel’s CooperationStrategy
by: Chun-Chen Chien, et al.
Published: (2014)

Elemental impurities analysis in name-brand and generic omeprazole drug samples
by: Fernanda C. Pinheiro, et al.
Published: (2020-02-01)

Safety of switching from brand-name to generic levetiracetam in patients with epilepsy
by: Bosak M, et al.
Published: (2017-08-01)

Comparison of Pharmaceutical Characteristics between Brand-Name Meropenem and Its Generics
by: Ping Yang, et al.
Published: (2021-09-01)

Patent Litigation Strategy between Generic and Brand Name Pharmaceutical Companies
by: Sun, Wei-Tung, et al.
Published: (2013)

Relationship between obesity and antipsychotic drug use in the adult population: A longitudinal, retrospective claim database study in Primary Care settings
by: Antoni Sicras-Mainar, et al.
Published: (2008-03-01)

Uso de recursos y costos asociados a las fracturas en mujeres españolas Use of resources and costs associated to fractures in spanish women
by: Antoni Sicras-Mainar, et al.
Published: (2012-09-01)

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study
by: Sicras-Mainar A, et al.
Published: (2019-12-01)

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
by: Ameet Sarpatwari, et al.
Published: (2016-02-01)

Costes y patrón de uso de servicios en pacientes que demandan atención por problemas mentales en asistencia primaria Patterns of health services use and costs in patients with mental disorders in primary care
by: Josep Serrat Tarrés, et al.
Published: (2007-08-01)